FDA Reports Declining 510(k) Times, And Other Improvements
This article was originally published in The Gray Sheet
Executive Summary
The most recent user-fee program trends report from FDA, with data current to March 31, 2014, shows improvements in 510(k) review metrics.
You may also be interested in...
FDA MDUFA III Performance, By The Numbers
Here's a snapshot of FDA's current premarket device review activity in seven interactive graphics.
Editors' Picks: Six Themes From 2014
Industry closely scrutinized FDA's premarket review performance as the agency took steps to streamline reviews and remake the U.S. postmarket surveillance system. Meanwhile: device mega-mergers accelerated; one of the most hotly anticipated medtech innovations faltered; and national elections swept in Republican control of Congress. Here is a look back at coverage and analysis from "The Gray Sheet" on six key themes for the medical device and diagnostics industry in 2014.
Consistency Among CDRH Review Divisions Improves, But Industry Wants More
A new report from the California Healthcare Institute shows a positive convergence of performance among FDA’s device review divisions, but the biomedical industry group thinks more policy reforms that build on models from the best performing CDRH divisions and branches might be warranted.